Pharsight

1. Drug name - ADVIL ALLERGY SINUS

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7863287	GLAXOSMITHKLINE	Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines	Feb, 2027 (4 years from now)

Drugs and Companies using CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2MG;200MG;30MG	TABLET;ORAL	Over the counter

2. Drug name - ANORO ELLIPTA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44874	GLAXOSMITHKLINE	Phenethanolamine derivatives for treatment of respiratory diseases	Mar, 2023 (5 months from now)
US7498440	GLAXOSMITHKLINE	Muscarinic acetylcholine receptor antagonists	Apr, 2025 (2 years from now)
US7439393	GLAXOSMITHKLINE	Phenethanolamine derivatives for treatment of respiratory diseases	May, 2025 (2 years from now)
US7488827	GLAXOSMITHKLINE	Muscarinic acetylcholine receptor antagonists	Dec, 2027 (5 years from now)
CN1976701A	GLAXOSMITHKLINE	Machrs Antagonist	May, 2012 (10 years ago)
CN101701006B	GLAXOSMITHKLINE	Phenethanolamine Derivatives For Treatment Of Respiratory Diseases	Sep, 2022 (23 days ago)
CN101701006A	GLAXOSMITHKLINE	Phenethanolamine Derivatives For Treatment Of Respiratory Diseases	Sep, 2022 (23 days ago)
CN1585633B	GLAXOSMITHKLINE	Phenethanolamine Derivatives For Treatment Of Respiratory Diseases	Sep, 2022 (23 days ago)
CN1585633A	GLAXOSMITHKLINE	Phenethanolamine Derivatives For Treatment Of Respiratory Diseases	Sep, 2022 (23 days ago)
CN103288793A	GLAXOSMITHKLINE	Phenethanolamine Derivatives For Treatment Of Respiratory Diseases	Sep, 2022 (23 days ago)
CN103288793B	GLAXOSMITHKLINE	Phenethanolamine Derivatives For Treatment Of Respiratory Diseases	Sep, 2022 (23 days ago)
IN212714B	GLAXOSMITHKLINE	Phenethanolamine Derivatives For Treatment Of Respiratory Diseases.	Sep, 2022 (23 days ago)
IN200400346P2	GLAXOSMITHKLINE	Phenethanolamine Derivatives For Treatment Of Respiratory Diseases.	Sep, 2022 (23 days ago)
IN255064B	GLAXOSMITHKLINE	4-[Hydroxy(Diphenyl)Methyl]-1-(2-[(Phenylmethyl)Oxy]Ethyl}-1-Azoniabicyclo[2.2.2.]Octane Bromide	Apr, 2025 (2 years from now)
IN200605413P1	GLAXOSMITHKLINE	Muscarinic Acetylcholine Receptor Antagonists	Apr, 2025 (2 years from now)
EP2042168B1	GLAXOSMITHKLINE	Inhalation Formulation Comprising Phenethanolamine Derivatives For The Treatment Of Respiratory Diseases	Sep, 2022 (23 days ago)
EP2042168A1	GLAXOSMITHKLINE	Inhalation Formulation Comprising Phenethanolamine Derivatives For The Treatment Of Respiratory Diseases	Sep, 2022 (23 days ago)
EP2570128A1	GLAXOSMITHKLINE	Muscarinic Acetylcholine Receptor Antagonists	Apr, 2025 (2 years from now)
EP2570128B1	GLAXOSMITHKLINE	Muscarinic Acetylcholine Receptor Antagonists	Apr, 2025 (2 years from now)
EP1740177A4	GLAXOSMITHKLINE	Muscarinic Acetylcholine Receptor Antagonists	Apr, 2025 (2 years from now)
EP1740177B1	GLAXOSMITHKLINE	Muscarinic Acetylcholine Receptor Antagonists	Apr, 2025 (2 years from now)
EP1740177A2	GLAXOSMITHKLINE	Muscarinic Acetylcholine Receptor Antagonists	Apr, 2025 (2 years from now)
EP1425001A1	GLAXOSMITHKLINE	Phenethanolamine Derivatives For Treatment Of Respiratory Diseases	Sep, 2027 (4 years from now)
EP1425001B1	GLAXOSMITHKLINE	Phenethanolamine Derivatives For Treatment Of Respiratory Diseases	Sep, 2027 (4 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309572	GLAXOSMITHKLINE	Muscarinic acetylcholine receptor antagonists	Apr, 2025 (2 years from now)
US8183257	GLAXOSMITHKLINE	Muscarinic acetylcholine receptor antagonists	Jul, 2025 (2 years from now)
US8511304	GLAXOSMITHKLINE	Medicament dispenser	Jun, 2027 (4 years from now)
US9333310	GLAXOSMITHKLINE	Medicament dispenser	Oct, 2027 (4 years from now)
US8113199	GLAXOSMITHKLINE	Counter for use with a medicament dispenser	Oct, 2027 (5 years from now)
US8161968	GLAXOSMITHKLINE	Medicament dispenser	Feb, 2028 (5 years from now)
US8534281	GLAXOSMITHKLINE	Manifold for use in medicament dispenser	Mar, 2030 (7 years from now)
US8746242	GLAXOSMITHKLINE	Medicament dispenser	Oct, 2030 (8 years from now)
US9750726	GLAXOSMITHKLINE	Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist	Nov, 2030 (8 years from now)
US11090294	GLAXOSMITHKLINE	Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist	Nov, 2030 (8 years from now)

Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.; Maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	POWDER;INHALATION	Prescription

3. Drug name - ARNUITY ELLIPTA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9333310	GLAXOSMITHKLINE	Medicament dispenser	Oct, 2027 (4 years from now)
US8113199	GLAXOSMITHKLINE	Counter for use with a medicament dispenser	Oct, 2027 (5 years from now)
US8161968	GLAXOSMITHKLINE	Medicament dispenser	Feb, 2028 (5 years from now)
US8201556	GLAXOSMITHKLINE	Medicament dispenser	Feb, 2029 (6 years from now)
US8534281	GLAXOSMITHKLINE	Manifold for use in medicament dispenser	Mar, 2030 (7 years from now)
US8746242	GLAXOSMITHKLINE	Medicament dispenser	Oct, 2030 (8 years from now)

Drugs and Companies using FLUTICASONE FUROATE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.05MG/INH	POWDER;INHALATION	Prescription
0.1MG/INH	POWDER;INHALATION	Prescription
0.2MG/INH	POWDER;INHALATION	Prescription

4. Drug name - CHILDREN'S ADVIL

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238640	GLAXOSMITHKLINE	Pharmaceutical suspension composition	May, 2024 (1 year, 7 months from now)

Drugs and Companies using IBUPROFEN ingredient

Treatment: NA

Dosage: SUSPENSION;ORAL

Strength	Dosage	Availability
100MG/5ML	SUSPENSION;ORAL	Over the counter

5. Drug name - CHILDREN'S ADVIL ALLERGY SINUS

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238640	GLAXOSMITHKLINE	Pharmaceutical suspension composition	May, 2024 (1 year, 7 months from now)

Drugs and Companies using CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SUSPENSION;ORAL

Strength	Dosage	Availability
1MG/5ML;100MG/5ML;15MG/5ML	SUSPENSION;ORAL	Over the counter

6. Drug name - NICORETTE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8323683	GLAXOSMITHKLINE	Flavoring of drug-containing chewing gums	Apr, 2028 (5 years from now)
US8940772	GLAXOSMITHKLINE	Nicotine lozenge composition	Apr, 2029 (6 years from now)
US8501164	GLAXOSMITHKLINE	Nicotine lozenge compositions	Jun, 2029 (6 years from now)

Drugs and Companies using NICOTINE POLACRILEX ingredient

Treatment: NA

Dosage: GUM, CHEWING;BUCCAL

Strength	Dosage	Availability
EQ 4MG BASE	GUM, CHEWING;BUCCAL	Over the counter

7. Drug name - TRELEGY ELLIPTA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44874	GLAXOSMITHKLINE	Phenethanolamine derivatives for treatment of respiratory diseases	Mar, 2023 (5 months from now)
US7498440	GLAXOSMITHKLINE	Muscarinic acetylcholine receptor antagonists	Apr, 2025 (2 years from now)
US7439393	GLAXOSMITHKLINE	Phenethanolamine derivatives for treatment of respiratory diseases	May, 2025 (2 years from now)
US7488827	GLAXOSMITHKLINE	Muscarinic acetylcholine receptor antagonists	Dec, 2027 (5 years from now)
CN1976701A	GLAXOSMITHKLINE	Machrs Antagonist	May, 2012 (10 years ago)
CN101701006B	GLAXOSMITHKLINE	Phenethanolamine Derivatives For Treatment Of Respiratory Diseases	Sep, 2022 (23 days ago)
CN101701006A	GLAXOSMITHKLINE	Phenethanolamine Derivatives For Treatment Of Respiratory Diseases	Sep, 2022 (23 days ago)
CN1585633B	GLAXOSMITHKLINE	Phenethanolamine Derivatives For Treatment Of Respiratory Diseases	Sep, 2022 (23 days ago)
CN1585633A	GLAXOSMITHKLINE	Phenethanolamine Derivatives For Treatment Of Respiratory Diseases	Sep, 2022 (23 days ago)
CN103288793A	GLAXOSMITHKLINE	Phenethanolamine Derivatives For Treatment Of Respiratory Diseases	Sep, 2022 (23 days ago)
CN103288793B	GLAXOSMITHKLINE	Phenethanolamine Derivatives For Treatment Of Respiratory Diseases	Sep, 2022 (23 days ago)
IN212714B	GLAXOSMITHKLINE	Phenethanolamine Derivatives For Treatment Of Respiratory Diseases.	Sep, 2022 (23 days ago)
IN200400346P2	GLAXOSMITHKLINE	Phenethanolamine Derivatives For Treatment Of Respiratory Diseases.	Sep, 2022 (23 days ago)
IN255064B	GLAXOSMITHKLINE	4-[Hydroxy(Diphenyl)Methyl]-1-(2-[(Phenylmethyl)Oxy]Ethyl}-1-Azoniabicyclo[2.2.2.]Octane Bromide	Apr, 2025 (2 years from now)
IN200605413P1	GLAXOSMITHKLINE	Muscarinic Acetylcholine Receptor Antagonists	Apr, 2025 (2 years from now)
EP2042168B1	GLAXOSMITHKLINE	Inhalation Formulation Comprising Phenethanolamine Derivatives For The Treatment Of Respiratory Diseases	Sep, 2022 (23 days ago)
EP2042168A1	GLAXOSMITHKLINE	Inhalation Formulation Comprising Phenethanolamine Derivatives For The Treatment Of Respiratory Diseases	Sep, 2022 (23 days ago)
EP2570128A1	GLAXOSMITHKLINE	Muscarinic Acetylcholine Receptor Antagonists	Apr, 2025 (2 years from now)
EP2570128B1	GLAXOSMITHKLINE	Muscarinic Acetylcholine Receptor Antagonists	Apr, 2025 (2 years from now)
EP1740177A4	GLAXOSMITHKLINE	Muscarinic Acetylcholine Receptor Antagonists	Apr, 2025 (2 years from now)
EP1740177B1	GLAXOSMITHKLINE	Muscarinic Acetylcholine Receptor Antagonists	Apr, 2025 (2 years from now)
EP1740177A2	GLAXOSMITHKLINE	Muscarinic Acetylcholine Receptor Antagonists	Apr, 2025 (2 years from now)
EP1425001A1	GLAXOSMITHKLINE	Phenethanolamine Derivatives For Treatment Of Respiratory Diseases	Sep, 2027 (4 years from now)
EP1425001B1	GLAXOSMITHKLINE	Phenethanolamine Derivatives For Treatment Of Respiratory Diseases	Sep, 2027 (4 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309572	GLAXOSMITHKLINE	Muscarinic acetylcholine receptor antagonists	Apr, 2025 (2 years from now)
US8183257	GLAXOSMITHKLINE	Muscarinic acetylcholine receptor antagonists	Jul, 2025 (2 years from now)
US8511304	GLAXOSMITHKLINE	Medicament dispenser	Jun, 2027 (4 years from now)
US9333310	GLAXOSMITHKLINE	Medicament dispenser	Oct, 2027 (4 years from now)
US8113199	GLAXOSMITHKLINE	Counter for use with a medicament dispenser	Oct, 2027 (5 years from now)
US8161968	GLAXOSMITHKLINE	Medicament dispenser	Feb, 2028 (5 years from now)
US8534281	GLAXOSMITHKLINE	Manifold for use in medicament dispenser	Mar, 2030 (7 years from now)
US8746242	GLAXOSMITHKLINE	Medicament dispenser	Oct, 2030 (8 years from now)
US11090294	GLAXOSMITHKLINE	Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist	Nov, 2030 (8 years from now)
US9750726	GLAXOSMITHKLINE	Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist	Nov, 2030 (8 years from now)

Drugs and Companies using FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

Treatment: Method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human, comprising contacting the receptor with an effective amount of umeclidinium, via topical application; Method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human, comprising contacting the receptor with an effective amount of umeclidinium, via inhalation; method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human, comprising contacting the receptor with an effective amount of umeclidinium, via topical application; Method of dispensing a combination medicament product from claimed delivery device, for example for the treatment of asthma or copd; Maintenance treatment of chronic obstructive pulmonary disease (copd) comprising the once per day administration of trelegy ellipta, 100 mcg fluticasone furoate/62.5 mcg umeclidinium/25 mcg vilanterol

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	POWDER;INHALATION	Prescription
0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	POWDER;INHALATION	Prescription

8. Drug name - VENTOLIN HFA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7832351	GLAXOSMITHKLINE	Actuation indicator for a dispensing device	Jun, 2023 (8 months from now)
US7832351 (Pediatric)	GLAXOSMITHKLINE	Actuation indicator for a dispensing device	Dec, 2023 (1 year, 2 months from now)
US7500444	GLAXOSMITHKLINE	Actuation indicator for a dispensing device	Feb, 2026 (3 years from now)
US7500444 (Pediatric)	GLAXOSMITHKLINE	Actuation indicator for a dispensing device	Aug, 2026 (3 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

Strength	Dosage	Availability
EQ 0.09MG BASE/INH	AEROSOL, METERED;INHALATION	Prescription

9. Drug name - ZEJULA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8436185	GLAXOSMITHKLINE	Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide	Apr, 2029 (6 years from now)
US8071623	GLAXOSMITHKLINE	Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors	Mar, 2031 (8 years from now)
CN101932572A	GLAXOSMITHKLINE	Pharmaceutically Acceptable Salts Of 2-{4-[(3S)-Piperidin-3-Yl]Phenyl}-2H-Indazole-7-Carboxamide	Nov, 2016 (5 years ago)
CN101415686A	GLAXOSMITHKLINE	Amide Substituted Indazole And Benzotriazole Derivatives As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors	Apr, 2027 (4 years from now)
CN101415686B	GLAXOSMITHKLINE	Amide Substituted Indazole And Benzotriazole Derivatives As Poly (Adp-Ribose) Polymerase (Parp) Inhibitor	Apr, 2027 (4 years from now)
CN101578279B	GLAXOSMITHKLINE	Amide Substituted Indazoles As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors	Jan, 2028 (5 years from now)
CN101578279A	GLAXOSMITHKLINE	Amide Substituted Indazoles As Poly(Adp-Ribose) Polymerase(Parp) Inhibitors	Jan, 2028 (5 years from now)
IN288260B	GLAXOSMITHKLINE	Amide Substituted Indazole And Benzotriazole Derivatives As Poly (Adpribose) Polymerase (Parp) Inhibitors	Apr, 2027 (4 years from now)
IN200808150P1	GLAXOSMITHKLINE	Amide Substituted Indazole And Benzotriazole Derivatives As Poly (Adp-Ribose)Polymerase (Parp) Inhibitors	Apr, 2027 (4 years from now)
EP2007733B1	GLAXOSMITHKLINE	Amide Substituted Indazole And Benzotriazole Derivatives As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors	Apr, 2027 (4 years from now)
EP2007733A1	GLAXOSMITHKLINE	Amide Substituted Indazole And Benzotriazole Derivatives As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors	Apr, 2027 (4 years from now)
EP2336120B1	GLAXOSMITHKLINE	Combinations Containing Amide Substituted Indazoles As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors	Jan, 2028 (5 years from now)
EP2805945A1	GLAXOSMITHKLINE	Amide Substituted Indazoles As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors	Jan, 2028 (5 years from now)
EP2336120A1	GLAXOSMITHKLINE	Combinations Containing Amide Substituted Indazoles As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors	Jan, 2028 (5 years from now)
EP2805945B1	GLAXOSMITHKLINE	Amide Substituted Indazoles As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors	Jan, 2028 (5 years from now)
EP2109608A1	GLAXOSMITHKLINE	Amide Substituted Indazoles As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors	Jan, 2028 (5 years from now)
EP2109608B1	GLAXOSMITHKLINE	Amide Substituted Indazoles As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors	Jan, 2028 (5 years from now)
EP2240466B1	GLAXOSMITHKLINE	Pharmaceutically Acceptable Salts Of 2-{4-[(3S)-Piperidin-3- Yl]Phenyl} -2H-Indazole-7-Carboxamide	Jan, 2029 (6 years from now)
EP2240466A1	GLAXOSMITHKLINE	Pharmaceutically Acceptable Salts Of 2-{4-[(3S)-Piperidin-3- Yl]Phenyl} -2H-Indazole-7-Carboxamide	Jan, 2029 (6 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071579	GLAXOSMITHKLINE	DNA damage repair inhibitors for the treatment of cancer	Aug, 2027 (4 years from now)
US8143241	GLAXOSMITHKLINE	DNA damage repair inhibitors for treatment of cancer	Aug, 2027 (4 years from now)
US8859562	GLAXOSMITHKLINE	Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer	Aug, 2031 (8 years from now)
US11091459	GLAXOSMITHKLINE	Niraparib compositions	Mar, 2038 (15 years from now)

Drugs and Companies using NIRAPARIB TOSYLATE ingredient

Treatment: A method of treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer associated with homologous recombination deficiency (hrd) positive status

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 100MG BASE	CAPSULE;ORAL	Prescription

Pharsight

Drug Patents owned by Glaxosmithkline

1. Drug name - ADVIL ALLERGY SINUS

2. Drug name - ANORO ELLIPTA

3. Drug name - ARNUITY ELLIPTA

4. Drug name - CHILDREN'S ADVIL

5. Drug name - CHILDREN'S ADVIL ALLERGY SINUS

6. Drug name - NICORETTE

7. Drug name - TRELEGY ELLIPTA

8. Drug name - VENTOLIN HFA

9. Drug name - ZEJULA

availability in other generic markets.

Click on the highlighted region to filter.

Pharsight

Drug Patents owned by Glaxosmithkline

1. Drug name - ADVIL ALLERGY SINUS

2. Drug name - ANORO ELLIPTA

3. Drug name - ARNUITY ELLIPTA

4. Drug name - CHILDREN'S ADVIL

5. Drug name - CHILDREN'S ADVIL ALLERGY SINUS

6. Drug name - NICORETTE

7. Drug name - TRELEGY ELLIPTA

8. Drug name - VENTOLIN HFA

9. Drug name - ZEJULA

availability in other generic markets. Click on the highlighted region to filter.

availability in other generic markets.

Click on the highlighted region to filter.